NASDAQ:ARCT prices gapped up on strong volume (10x the average) during the previous earnings before moving up to the $28 resistance level. The $28 price level served as resistance previously back during feb and april of last year so it was not surprising to see prices encountered resistance at that level. Prices moved sideways more or less at the top right side...
Good company with new technology - Seems like we finally have hit the floor, now ready for a bullish move to the upside.
I will be shorting Arcturus Therapeutics to a range of $10-$12, and exit there.
Arcturus Therapeutics Holdings Inc. $ARCT is set to be EBITDA positive in 2022 with a massive change in its revenue from 24.05M in 2021 to 326.44M in 2022. This is 12.57x increase in revenue. These numbers are estimates, but even with a large error margin we should see a drastic change in the price. Moreover, the decline from ATH was 80% and the price has been in...
Monthly candle right around historical S+R, a monthly and or weekly close above $34.50 takes ARCT to $44ish. Could be fire
Backtest + clean bounce off last year's gap up breakout. Oversold and ready for reversal, very fire
ARCT fell a whopping 66% the past 2 days. The catalyst was the inability of its COVID vaccine to produce levels of antibodies comparable to other vaccines in development or already developed. You can check more here: www.investors.com It found support around $41.5 and moved about 12% to the upside to only fall again. It is currently hovering over the $44.3...